Data completeness
3/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 13h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABILIFY MYCITE KIT is an oral tablet formulation of aripiprazole (a dopamine D2/D3 receptor partial agonist) combined with digital ingestion tracking technology for adherence monitoring. The product treats psychiatric indications where medication adherence is clinically significant. It represents a digital health innovation layered onto an established antipsychotic backbone.
Peak7.1 years to LOE
Product is at peak lifecycle with 7+ years of patent protection remaining; teams are stabilized in size with focus on optimization rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ABILIFY MYCITE KIT offers exposure to the intersection of traditional pharma and digital health innovation, with career value in understanding adherence monitoring, data privacy compliance, and payer negotiation around digital services. The peak lifecycle stage with 7+ years of patent protection provides stable, mature team opportunities but limited growth runway before LOE approaches.
Brand Manager
Worked on ABILIFY MYCITE KIT at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.